We do not fully understand why the remaining α‐MN in FUS‐ALS cases that bear large aggregates show reduced immunoreactivity of DYRK3 both in the nucleus as well as in the cytoplasm, nor why the fibroblasts from ALS patients analyzed do not properly upregulate DYRK3 mRNA during the stress recovery phase. The gene discussed is DYRK3; the disease is amyotrophic lateral sclerosis.